Bayer and Exscientia Collaborate to Leverage the Potential of Artificial Intelligence in Cardiovascular and Oncology Drug Discovery

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities.
Source: eHealth News EU - Category: Information Technology Tags: Featured Industry Business and Industry Source Type: news